Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Marex Group Limited Ordinary Shares (MRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Marex Group Limited Ordinary Shares — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.5 (market cap $31.07B), while Marex Group Limited Ordinary Shares trades at $68.92 (market cap $5.18B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 6× Marex Group Limited Ordinary Shares's market cap, and Marex Group Limited Ordinary Shares pays the higher dividend (0.89%). Which is the better fit depends on your goals.
| GEHC | MRX | |
|---|---|---|
Market Cap | $31.07B | $5.18B |
Volume | 3,443,020 | 794,309 |
Sector | Health | Financials |
52-Week High | $88.16 | $78.27 |
52-Week Low | $59.48 | $29.92 |
Enterprise Value | $39.53B | $8.26B |
Dividend Yield | 0.23% | 0.89% |
Typical Hold Time | — | 3 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
MRX trades at $71.95, down 0.47% on the day, with a neutral technical signal despite bullish moving averages. The company demonstrates strong fundamentals with a P/E of 14.62 and robust profitability, including a 9.69% net income margin and 27.57% ROE. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $1.64 surpassing the $1.36 estimate. Positive news includes record H1 2026 results and strategic developments in financial infrastructure.
The outlook for MRX is positive, supported by strong earnings momentum, a 100% buy rating from analysts, and a consensus price target of $83.67 implying significant upside. Key risks include execution of its acquisition strategy and market volatility. The stock's current valuation and growth trajectory present a compelling opportunity, though investors should monitor debt levels and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Marex Group Limited Ordinary Shares
Marex Group provides financial services across commodities, financial markets, and corporate clients. Its services include clearing, agency and execution, market making, hedging, and securities services.
Read more on MRX →
